Sex Hormones and Gender Influence the Expression of Markers of Regulatory T Cells in SLE Patients

Ram P. Singh1* and David S. Bischoff1,2

1 Research Service, Veteran Administration Greater Los Angeles Healthcare System, Los Angeles, CA, United States; 2 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Regulatory T cells have been implicated in the regulation and maintenance of immune homeostasis. Whether gender and sex hormones differentially influence the expression and function of regulatory T cell phenotype and their influence on FoxP3 expression remains obscure. We provide evidence in this study that the number and percent of human regulatory T cells (Tregs) expressing CD4+ and CD8+ are significantly reduced in healthy females compared to healthy males. In addition, both CD4+CD25+hi and CD8+CD25+hi subsets in healthy males have a 2-3 fold increase in FoxP3 mRNA expression compared to healthy females. Female SLE patients, compared to healthy women, have elevated plasma levels of estradiol and decreased levels of testosterone. Higher levels of testosterone correlate with higher expression of FoxP3 in CD4+CD25+CD127low putative Tregs in women with SLE. Incubation of CD4+ regulatory T cells with 17β-estradiol at physiological levels generally decreased FoxP3 expression in females with SLE. These data suggest that females may be more susceptible than males to SLE and other autoimmune diseases in part because they have fewer Tregs and reduced FoxP3 expression within those cells due to normal E2 levels which suppress FoxP3 expression. In addition, low levels of plasma testosterone in women may further reduce the ability of the Tregs to express FoxP3. These data suggest that gender and sex hormones can influence susceptibility to SLE via effects on regulatory T cells and FoxP3 expression.

Keywords: sex hormones, gender, regulatory T cells, systemic lupus erythematosus, 17β-estradiol

INTRODUCTION

Many autoimmune diseases including lupus are gender biased, with females outnumbering males 9:1 (1–5). Emerging evidence shows that sex hormones influence the expression and function of regulatory cells in both mice and humans (6) and that regulatory T cells (Tregs), which play an important role in the regulation and maintenance of a normal immune responses, are impaired in numbers or in function in many autoimmune diseases including SLE (7–9). Both CD4+ and CD8+ Tregs in the peripheral immune system have important roles in suppressing autoimmune disease (10–15). Impaired development and function (16–19) or removal (20–23) of Tregs can also promote the development of autoimmunity. We have shown previously that Tregs suppress autoreactive T and B cells in lupus-prone mice and protect against disease (24–27). Some recent reports suggest a decreased percentage of CD4+CD25+ cells (28–30); whereas, other reports seem to indicate normal or increased numbers of circulating Tregs (31–35) in active SLE patients. These differences may be...
due to differences in phenotyping methods, analyses, disease status, or therapies. Our own research points to a significantly decreased percentage of $T_{\text{regs}}$ in our SLE cohort. However, gender-based differences in the roles of $T_{\text{regs}}$, expression of FoxP3, and their regulatory capacities have not been thoroughly studied.

Recent studies have shown that FoxP3 plays a significant role in regulatory T cell differentiation, function, and the prevention of auto-reactivity (8, 36, 37). FoxP3 is a critical transcription factor essential for determining the phenotype, development, and function of $T_{\text{regs}}$. FoxP3 deficiency or mutation results in the "Scurfy" phenotype in mice (38) and in humans results in IPEX (Immune dysregulation, Polyendocrinopathy, X-linked) syndrome (8, 9, 39–41).

Sex hormones have been known to play an important role in regulating lupus both in human and animal models (42, 43). Estrogen has been shown to increase calcineurin in T cells of SLE patients but not in age and sex matched healthy controls (44, 45). These previous studies did not examine the role of $T_{\text{regs}}$ in SLE patients. A recent study identified the expansion of CD4$^+$CD25$^+$ and FoxP3$^+$ $T_{\text{regs}}$ during the follicular phase of the menstrual cycle in healthy females and found that an increase in $T_{\text{regs}}$ correlated with changes in serum estradiol levels (46). In healthy males, testosterone antagonists have been shown to cause significant decreases (~30%) in the percentage of CD4$^+$CD25$^+$ T cells in comparison with baseline and with subjects in the placebo group. This decline normalized with the return of natural hormone levels after the antagonists were discontinued (47). In males with SLE, imbalances in estrogens and androgens could contribute to susceptibility to the disease (48–52).

Testosterone suppresses both IgG anti-dsDNA antibody and total IgG production in PBMCs from SLE patients (53, 54). Low levels of plasma androgens was reported (55) and androgen administration has been demonstrated to improve disease activity (56) in women with active SLE disease. However, this study (56) did not evaluate $T_{\text{reg}}$ function or the expression of FoxP3.

In the present study, we provide evidence that sex hormones and gender influence both the number and phenotype of $T_{\text{regs}}$ and the $T_{\text{reg}}$ expression of FoxP3 differentially in men and women and also in SLE patients and healthy controls. Notably, we have found that plasma levels of estradiol are increased and testosterone levels are decreased in SLE females compared to healthy females. Furthermore, we have found that $T_{\text{reg}}$ exposure to testosterone in vitro increases FoxP3 expression in SLE females. Finally, we have demonstrated that plasma concentrations of testosterone in SLE females positively correlates with levels of FoxP3 expression. These data suggest that sex hormones and gender play pivotal roles in the regulation and maintenance of immune responses and provide novel evidence for a modulatory role of 17β-estradiol and androgen (DHT) in the phenotype and regulation of immune responses in autoimmunity.

**MATERIALS AND METHODS**

**Subjects**

We enrolled 27 subjects who were 18 years or older and fulfilled the American College of Rheumatology revised criteria for the classification of SLE (57, 58) and 23 healthy donors (19–70 years of age) with no history of autoimmune disease. Patients with comorbid conditions were excluded from the study. Disease activity was recorded based on the SLE disease activity index (SLEDAI) (59). For estradiol and testosterone measurement, we obtained control and SLE plasma samples from the UCLA Rheumatology biobank. The study was approved by the Institutional Review Board of the University of California Los Angeles. Written informed consent was obtained from each subject who participated in the study.

**Cell Isolation and Preparation**

T cell enriched peripheral blood mononuclear cells (PBMCs) were isolated on a density gradient (Histopaque-1077, Sigma-Aldrich, St. Louis, MO, USA) from blood samples of lupus patients and healthy volunteers. Lymphocytes were washed twice in serum free media. Red blood cells (RBC) were lysed with RBC lysing solution (Sigma-Aldrich, St. Louis, MO, USA). CD4$^+$CD25$^{hi}$CD127$^{low}$ and CD8$^+$CD25$^{hi}$CD127$^{low}$ $T_{\text{regs}}$ were sorted after staining using a FACS Aria flow cytometer (BD Biosciences) for sex hormone experiments.

**Immunophenotyping and Flow Cytometry**

Peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers were stained with CD4-FITC, clone (RPA-T4); CD8-PerCP, clone (SK1); CD25-APC, clone (BC96); and CD127-PE, clone (hIL7R-M21) fluorochrome-conjugated monoclonal antibodies (mAb). Intracellular staining for FoxP3 (clone-PCH101) was performed after cell surface staining by fixation and permeabilization as per manufacturer protocol (eBiosciences, San Diego, CA). The antibodies for cell surface staining and isotype controls were from BD Biosciences, eBiosciences, and from BioLegend. (San Diego, CA). Data were collected using FACSCalibur (BD Biosciences) and analyzed by BD Cell Quest software (Becton-Dickinson, Mountain View, CA) or FCS De Nova software (Thornhill, Ontario, Canada).

**Cell Culture**

PBMCs and sorted CD4$^+$CD25$^{hi}$CD127$^{low}$ $T_{\text{regs}}$ (1-2x10$^6$ cells) were cultured with the sex hormones 17β-estradiol (30, 60–100, 500 pg/ml) or testosterone (30, 60, 100, 500 pg/ml), or with TGFβ (20 ng/ml) with and without fetal calf serum in complete media for 24–72 h. After culture, supernatants were obtained; cells were washed and stained for FACS analyses, and lysed for RNA and Western blot analyses.

**Abbreviations:** E2, 17β-estradiol; $T_{\text{regs}}$, regulatory T cells; RT-PCR, real-time PCR; SLE, systemic lupus erythematosus; PBMC, peripheral blood mononuclear cells; TGF-β, transforming growth factor beta; CD25, IL-2 receptor α chain; FoxP3, Forkhead box protein-3; FACS, fluorescence-activated cell sorting.
ELISA
Estradiol and testosterone levels were measured in plasma and culture supernatants by commercial ELISA (Calbiotech, Inc., Spring Valley, CA) as per manufacturer instructions.

RNA Isolation and Real Time PCR
RNA was isolated from sorted and cultured Tregs with TRIzol (Invitrogen) as per the manufacturer’s protocol. Real time PCR was used to analyze mRNA gene expression as described earlier (1, 26, 27). Human FoxP3 specific primers and probes were synthesized from Applied Biosystems. Human FoxP3 primer and probe sequences are as follows: FoxP3 forward, 5′-TCTTCTCGGTATAAAAGCAAAGTTGTT-3′; reverse, 5′-GTGAAGTGGACTGACAGAAAGGAT-3′; probe, 6FAM-TGATACGTGACAGTTCCACAAAGCCA-TAMRA. Human GAPDH primers and probes were obtained from Applied Biosystems. The amplification primers were used at 900 nM and probes at 200 nM. All samples were run in duplicate. Data was normalized with the house-keeping gene GAPDH.

Statistical Analyses
Data was analyzed using Prism 4.0 (GraphPad Software, San Diego, CA). Comparisons were performed using paired one- or two-tailed test. Results are expressed as mean ± SEM. p < 0.05 was considered significant.

**FIGURE 1** | The percentage of CD4+ and CD8+ expressing characteristics of regulatory T cells are significantly reduced in SLE patients compared to gender and age matched healthy controls. Representative FACS analysis from PBMC of active female SLE patients compared with healthy controls (A,B,D,F,G). Peripheral blood mononuclear cells (PBMC) were isolated from 20 to 30 ml of blood obtained from SLE patients and healthy controls. 10,000 cells were gated and analyzed by FACS. Representative FACS analysis of FoxP3+ T cells (B) with percent of positive cells in the Upper-Right quadrant indicated were analyzed after gating of CD4+ T cells and CD8+ T cells from PBMC. (C) Cumulative data of CD4+FoxP3+ T cells in healthy controls (n = 14) and SLE patients (n = 25). (D) Representative FACS analysis of CD8+FoxP3+ T cells from PBMC of SLE patient vs healthy control. (E) Cumulative data of CD8+FoxP3+ T cells in healthy controls (n = 13) and SLE patients (n = 16). (F) Representative FACS analysis of CD4+CD25+ T cells from SLE patient vs. healthy control. (G) Representative FACS analysis of CD8+CD25+ T cells from SLE patient vs. healthy control. (H) Cumulative data of CD4+CD25+FoxP3+ T cells in healthy controls (n = 10) and SLE patients (n = 12). p values indicating significant differences are shown in each panel (C,E,F). *p < 0.05, **p < 0.01, ***p < 0.001.
RESULTS

CD4+CD25hiFoxP3+ and CD8+CD25hiFoxP3+ Tregs Are Reduced in SLE Patients

In order to determine the number, phenotype, and homeostatic regulation and effects of sex hormones on Tregs in lupus patients compared to healthy controls, we performed an extensive immunophenotyping of PBMCs from each group (see gating scheme Figure 1A). Treg cells were identified as those cells expressing FoxP3 and CD25+high. We found that lupus patients exhibited significantly reduced percentages of CD4+FoxP3+ (p < 0.0041) and CD8+FoxP3+ T cells (p < 0.0102) when compared to healthy controls (Figures 1A–E). We also characterized levels of CD4+CD25+ (Figure 1F) and CD8+CD25+ T cells (Figure 1G) between healthy control and SLE patient and found that the percentage of CD4+CD25+hiFoxP3+ Tregs in peripheral blood was also significantly reduced in patients with SLE relative to healthy controls (Figure 1H; p < 0.0005). Collectively these data demonstrate that lupus patients have reduced percentages of both CD4+ and CD8+ Tregs.

CD4+CD25hi and CD8+CD25hi T Cells From Healthy Males Have Higher FoxP3 mRNA Levels Than Healthy Females

Healthy males had significantly higher percentages of CD4+CD25+hi and CD8+CD25+hi Tregs relative to healthy females (Figures 2A,B; p < 0.007 and p < 0.02). Since lupus is a gender-biased disease with a female to male ratio of 9:1, we determined whether FoxP3 expression in healthy male and female individuals varies in their regulatory T cell compartments. FoxP3 expression in CD4+ and CD8+ regulatory subsets, CD4+CD25+hi and CD8+CD25+hi T cell subsets were sorted by FACS. The sorted cells were subjected to RNA isolation from both healthy male and female subjects. We found that CD4+CD25+hi and CD8+CD25+hi subsets of healthy males had 2-3 times higher FoxP3 mRNA compared to healthy females (Figures 2C,D). Overall, we found that circulating CD4+CD25+high and CD8+CD25+high T cells are higher in healthy males than healthy females and, although, FoxP3 expression is decreased in both CD4+ and CD8+ T cells, it was only significantly decreased within the CD4+ T cell compartment.

Females Have Less Total FoxP3 Message in PBMCs Relative to Males; Evidence Suggests That TGFβ Promotes FoxP3 Expression in Both Sexes

Having examined the expression of FoxP3 in CD4+ and CD8+ Tregs of healthy males and females, we were interested to see whether transforming growth factor-β (TGFβ) promotes FoxP3 expression differently in whole peripheral blood mononuclear cells (PBMCs) of healthy males and females. Transforming growth factor-β (TGFβ) is a multifunctional cytokine regulating T cell biology (60, 61). It has been shown to induce FoxP3+ T regulatory cells from CD4+CD25− precursors (12, 62, 63). To address TGFβ effects on FoxP3 expression in healthy males and females, PBMCs were obtained, total RNA isolated, and real-time PCR performed to analyze FoxP3 expression. We found that female have less FoxP3 expression compared to age matched male healthy subject (Figure 3A). Overall, TGFβ increased FoxP3 expression in both healthy male and healthy female PBMCs (Figure 3B) however, the fold increase of FoxP3 expression was less in healthy females than in healthy males. These findings of a lower response to TGFβ in terms of expression of FoxP3— a classical marker of Tregs—in healthy females compared to healthy males might be one explanation of why SLE and other autoimmune disorders are predominantly expressed in females.

Female SLE Patients Have Altered Sex Hormone Levels—Increased Plasma Estradiol Levels and Decreased Testosterone Levels

Since chronic exposure to estradiol leads to activation of pro-inflammatory cells and genes, we measured 17β-estradiol levels in
SLE patients and age- and sex-matched controls. We found that female SLE patients have significantly increased plasma estradiol levels compared to healthy controls (Figure 4A). We also found that testosterone levels were decreased in female SLE patients compared to healthy female controls (Figure 4B).

Sex Hormones Influence CD4, CD25, and FoxP3 Expression Differentially in Healthy Males and Females and in SLE Female PBMCs

It is not clear whether sex hormones influence CD4, CD25 and FoxP3 expression differentially in humans, both healthy and in SLE patient cells. To address this, we isolated PBMCs from healthy male and female volunteers and cultured their PBMCs with different concentrations of 17β-estradiol (E2). In preliminary in vitro experiments using different concentrations of E2 (30–150 pg/ml), we determined that maximal responses in both healthy and SLE individuals occurred at the 30–60 pg/mL range (data not shown). Of significance, we found that incubation with E2 at physiologic range (60 pg/ml) significantly increased CD4, CD25, and FoxP3 (mean fluorescence intensity) expression in PBMCs from a healthy female (Figures 5A–C) but not in PBMCs from a healthy male (Figures 5D–F). In contrast, in SLE patients (both males and females) PBMCs treated with E2 at a physiological dose (60 pg/ml) was associated with significantly reduced FoxP3 mRNA expression (Figures 6A,B). These differences in response to E2 in SLE patients’ immune cells vs. healthy cells suggest that the disease-inflammatory microenvironment may play a significant role. Next, we wanted to see how CD4+CD25− T cells from SLE patients would respond to E2. We found that CD4+CD25− T cells treated with E2 were unable to drive FoxP3 protein expression (Figure 6C) and that the mean fluorescence intensity of FoxP3 was significantly (p < 0.04) decreased in E2-treated CD4+CD25− T cells (Figure 6D). These data suggest that in healthy females E2 promotes an increase in regulatory T cell numbers and FoxP3 expression; whereas, females with SLE have defective regulatory T cell responses to E2 at physiologic levels. Therefore, females with SLE do not expand Tregs normally in response to estradiol stimulation.

Androgen/Testosterone Increases the Expression of FoxP3 mRNA and Protein in Regulatory T Cells of SLE Patients

In the present study, we also tested the androgen effect on isolated CD4+CD25+CD127low Tregs in female SLE patients. Isolated cells were cultured with testosterone (100 ng/ml) and then lysed, RNA isolated, and RT-PCR performed. We found that treatment with testosterone/DHT (100 ng/mL) significantly increased FoxP3 mRNA expression in SLE patient’ CD4+ Tregs (Figure 7A). The positive effect of testosterone on FoxP3 expression is further suggested by the data shown in Figure 7B, which indicates that plasma concentrations of testosterone in females with SLE correlates significantly with the expression of FoxP3 in their CD4+CD25+CD127low T cells. Furthermore, we found that incubation with androgen increased the expression of total FoxP3 protein in the PBMCs of female SLE patients (Figure 7C). These data suggest that androgens positively regulate FoxP3 expression in SLE patients.

DISCUSSION

Environmental factors, genetic defects, and hormones can regulate immune responses and therefore may influence SLE susceptibility (64–67). Regulatory T cells (Tregs) play a key role in maintaining immune homeostasis including the prevention of autoimmunity, maintenance of self-tolerance, and regulation
FIGURE 5 | Estrogen increases expression of CD4, CD25, and FoxP3 in vitro in a healthy female subject but not in a healthy male subject. PBMCs (2–4 × 10^6) were isolated from a healthy female and a healthy male subject and cultured for 24–48 h range with physiological concentrations of E2 (60 pg/ml). Estrogen increases CD4 and CD25 cell surface expression and intracellular FoxP3 expression in a healthy female PBMCs (A–C). These effects were not seen in a healthy male PBMCs cells (D–F).

of immune responses against infection (68–70). The functional failure of T\textsubscript{reg} can result in development of autoimmune diseases including SLE (18, 71–73). Regulatory B cells (B\textsubscript{reg}) and myeloid-derived suppressor cells (MDSC) (74–79) and type1 regulatory T cells (CD4\textsuperscript{+}IL-10\textsuperscript{+}FoxP3\textsuperscript{−}) (80–85) have an immunosuppression role and promote immune tolerance. Genetic polymorphisms in the FoxP3 gene and imbalances of regulatory T cells and autoimmunity have also been reported (86) as-well-as polymorphisms of genes involved in T\textsubscript{reg} activation and function (87). Gender effects have also been reported.

Women are more prone than men to the development of autoimmune diseases including SLE (3, 4) and the role of sex hormones (17β-estradiol and androgen) has been demonstrated in SLE (88). The female sex hormone (estrogen) contributes to the pathogenesis of SLE by activating T cells and by modulating the function of regulatory T cells (89–91). However, it is not clear whether sex hormones and/or gender regulate the function of these regulatory cells or expression of markers including FoxP3 differentially in humans.

The role of sex hormones (17β-estradiol and androgen) has been demonstrated in SLE (88). The female sex hormone (estrogen) contributes to the pathogenesis of SLE by activating T cells and by modulating the function of regulatory T cells (89–91). In addition, an association of single-nucleotide polymorphisms in the FoxP3 gene have been correlated with SLE susceptibility (92). However, it is not clear whether sex hormones and/or gender regulate the function of these regulatory cells or expression of markers including FoxP3 differentially in humans. In the present study, we did not address the issue of gene polymorphisms or the possibility that individual SNPs may play a significant role in healthy T\textsubscript{reg} populations which have low FoxP3 expression. Future study will be needed to address these possibilities. Previous studies have shown that estradiol treatment of PBMCs affects T cells, B cells, and monocytes (54, 93, 94); and gender differences in estrogen receptor (ER) expression were documented (95). However, the effect of gender and sex hormones on the phenotype and function of T\textsubscript{reg} and expression of FoxP3 in SLE patients compared to healthy controls is less well studied. Recent evidence in a mouse model of autoimmune diseases indicates that female sex hormone (17β-estradiol-E2) influences the expression of FoxP3 and T\textsubscript{reg} number and function. Further, estradiol has been shown to influence the activation and function of many immune cells (74, 93) including CD4\textsuperscript{+} (Th1, Th2, Th17, and T\textsubscript{reg}) and CD8\textsuperscript{+} T cells (96–98).

It has been reported that estrogen exposure directly activated T cells through the cell membrane estrogen receptor (99) and that 17β-estradiol receptors are differentially expressed in women with SLE (100).

Estrogen binds to nuclear receptors (ER\textsubscript{α} and ER\textsubscript{β}) on various cells, including CD4\textsuperscript{+} T cells, thus altering the rate of gene transcription (48-51). It also acts independently of ER (estrogen receptor) through alterations in the plasma membrane. Exposure of T cells to 17β-estradiol stimulates kinase activation and calcium flux. In normal mice, administration of physiologic doses of 17β-estradiol to ovariectomized females increased 2-to-3-fold the numbers of CD4\textsuperscript{+}CD25\textsuperscript{+} and CD4\textsuperscript{+}FoxP3\textsuperscript{+} T cells in PBL, spleens and lymph nodes, suggesting that 17β-estradiol in the absence of other ovarian hormones strongly influences expansion
of T\textsubscript{reg} (101). In vivo or in vitro exposure to 17\textbeta\textsuperscript{-}estradiol increases CD4\textsuperscript{+}CD25\textsuperscript{+} T cell numbers and FoxP3 expression in Experimental Autoimmune Encephalomyelitis (EAE) (102).

Male hormones (androgens) also influence the immune response in many diseases including SLE (47). In males with SLE, imbalances in both estrogens and androgens could contribute to increased susceptibility to the active disease (48–52). Earlier studies indicated that testosterone suppressed both IgG anti-dsDNA antibody and total IgG production in PBMCs from SLE patients (53, 54). Androgen administration (of prasterone, which can be metabolized to testosterone) has recently been demonstrated to improve disease activity in females with SLE (56). The effect of testosterone on CD4\textsuperscript{+} T\textsubscript{reg} and FoxP3 expression, stability, and plasticity in SLE patients is not clear and has not been studied extensively. Although recent evidence suggests that FoxP3 protein stability is controlled by several proteins including cyclin dependent kinase–2 (CDK-2) (103), Pim-2 kinase (104), Nemo-like kinase, and CNS2 (non–coding sequence 2 demethylation by TET (ten-eleven translocation) protein (105, 106). However, the molecular mechanisms that control FoxP3 stability and T\textsubscript{reg} plasticity remains to be identified in SLE.

In the present study, we demonstrate that the percentage of CD4\textsuperscript{+} and CD8\textsuperscript{+} T\textsubscript{reg} are significantly reduced in SLE patients compared to gender and age matched healthy controls (Figure 1); and that the percentage of both CD4\textsuperscript{+} and CD8\textsuperscript{+} T\textsubscript{reg} is reduced in healthy females compared to healthy males. Our data is the first report that healthy male cells express higher FoxP3 mRNA levels than healthy female cells (Figure 2). We show that female SLE patients have increased plasma levels of estradiol (Figure 4) and that incubation of CD4\textsuperscript{+} T\textsubscript{reg} with 17\beta-estradiol (at physiological levels) either maintains or decreases FoxP3 expression in females with SLE, in contrast to inducing a significant increase in CD4\textsuperscript{+} T\textsubscript{reg} in healthy females (Figures 5, 6). We further show that TGF\beta treatment induces FoxP3 expression in PBMC of both healthy males and females, but at a larger degree in males than healthy females (Figure 3). At the mechanistic level, we demonstrate that estrogen increases expression of CD4, CD25, and FoxP3 in a healthy female but not in a healthy male subject (Figure 5). Finally, at the clinical and translational significance level, we showed for the first time that in female SLE patients (1) testosterone levels are reduced (Figure 4); (2) testosterone exposure increases the expression of FoxP3 mRNA in T\textsubscript{reg} (Figure 7); and (3) that the plasma levels of testosterone positively correlates with FoxP3 mRNA (Figure 7). Thus, our data suggest that sex hormones and gender influences the expression of FoxP3 and regulatory T cells differentially in SLE.

![FIGURE 6](image-url) Lupus patient immune cells respond to E2 with a decrease in FoxP3 expression. Estrogen decreases expression of FoxP3 in both female and male SLE patient PBMCs. Lupus patient PBMCs (2–4 × 10\textsuperscript{6} cells) were isolated and cultured (24–48 h range) with E2 at physiological concentrations (60 pg/ml). RNA was isolated, and real time PCR was performed with FoxP3 primers and probes. GAPDH was used as the house keeping gene. FoxP3 mRNA expression was reduced in female (n = 5) and male (n = 3) SLE pts (A,B). (C) Estrogen decreases FoxP3 protein in CD4\textsuperscript{+}CD25\textsuperscript{−} T cells from SLE patients. CD4\textsuperscript{+}CD25\textsuperscript{−} T cells were isolated from female SLE patient cells (n = 3) and cultured for in the 24–48 h range with E2 at 30 pg/ml concentration. FoxP3 intracellular protein was measured by FACS. (D) Mean fluorescence intensity (MFI) decreases in CD4\textsuperscript{+}CD25\textsuperscript{−} T cells from SLE patients treated with E2. *p < 0.05.
We postulate that women are predisposed to SLE and to the maintenance of disease activity in part because of their relatively high levels of estradiol (E2), and their low levels of testosterone and related active metabolites. We also suggest that the sex hormone (estradiol that has higher concentrations in healthy females) work in part by suppressing the numbers and functional activity of CD4+ Tregs, with resultant inadequate suppression of CD4+CD25+ effector T cells and of autoantibody-producing B cells. Our data suggest that CD4+CD25+hi and CD4+FoxP3+ T cells are lower in numbers in women with SLE than in matched healthy controls, and that these cells are relatively insensitive to E2 stimulation at the levels that increase FoxP3 expression in normal Tregs but not in SLE. Our results are in-line with other investigators who found that estradiol treatment enhances increased expression of CD25+ T cells and increased FoxP3 expression in mice treated with estradiol (102). Furthermore, estradiol treatment increased Treg numbers and functions and induces FoxP3 expression both in vitro and in vivo (6). These data indicate that lupus patient’s immune cells (PBMCs) behave differently than those from healthy subjects when they are cultured in vitro with 17β-estradiol (Figure 6).

Androgen-induced immunosuppression was reviewed recently (107) in both sexes and shown to affect the differentiation and function of Tregs differently in men and women. In vivo administration of androgens to women with adrenal insufficiency and rats with experimental autoimmune orchitis has been shown to increase Treg numbers (108, 109). Further it was suggested that, androgens are capable of directly converting peripheral T cells into Tregs in women. However, in a contradicting report it was suggested that androgens interfere with Treg function in men, as occurs in a mouse model of Sjögren’s syndrome which predominantly affects male mice (110). Further it has been shown that administration of 5-dehydroepiandrosterone (DHEA), which is metabolized to testosterone, reduces disease activity in women with SLE (56). However, this DHEA study did not evaluate the expression of FoxP3 nor regulatory T cell numbers or function. In our current study, testosterone significantly increases FoxP3 expression in CD4+CD25+hi cells from females with SLE in vivo. Furthermore, we showed that testosterone increases the expression of FoxP3 mRNA in female SLE patient’s Tregs (Figure 7A). In addition, we showed that plasma concentrations of testosterone positively correlated in those females with the expression of FoxP3 in their CD4+CD25+hi T cells (Figure 7B) suggesting that this response to testosterone may be normal in women with SLE, in contrast to their response to estradiol.

Our data is in agreement with a previous study which showed that androgen causes expansion of Tregs and a significant androgen-dependent increase of FoxP3 expression in human T cells from women; however, this response was not seen in males. The study also identified a functional androgen response element (ARE) within the FoxP3 locus (111) and showed that binding of the androgen receptor (AR) to the ARE leads to epigenetic changes. The authors were able to show that the FoxP3 gene is more responsive to androgen treatment in T cells isolated from women than in men, indicating gender-specific androgen signaling. These studies, together with our data, demonstrate that healthy females may be more susceptible than males to SLE and other autoimmune diseases in part because females have fewer Tregs with reduced FoxP3 expression within those cells. In addition, females with SLE have less ability to generate CD4+ Tregs in response to physiologic concentrations of 17β-estradiol in comparison to healthy females; whereas, an active testosterone metabolite can increase the generation of CD4+ Tregs in SLE females. The responsiveness of female T cells to induce or transform into Tregs, under the effect of androgen, may provide a mechanistic basis to control excessive and damaging immune responses (autoimmunity). Future studies will be required addressing the exact mechanism of this immune homeostasis.

In summary, our results provide novel evidence for a functional modulatory role of sex hormones (estradiol and testosterone) on Treg numbers and function in female SLE patients.
androgen) in the differentiation of Treg cells in SLE. Further, we provided evidence that androgen effects the regulation of the FoxP3 expression on T regulatory cells differentially in women and men.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by UCLA IRB. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RPS conceived the idea, designed the experiments, performed the experiments, obtained data, analyzed, wrote the manuscript, and obtained funding. DS8 analyzed the data, figure drawing and edited the manuscript. Both authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by NIH grants AR54034, AI 083894, AI65645 to RPS, UCLA Senate Core Grant to Bevra Hahn and RPS, UCLA Oppenheimer Clinical Seed Grant and American Autoimmune Related Disease Association grant to RPS.

ACKNOWLEDGMENTS

We would like to thank all the patients, volunteers, and the UCLA Rheumatology clinicians who participated in the study by providing blood samples for our analysis. We also thank the UCLA Flow Cytometry Core Facility for cell sorting and FACS experiments, Ravi Dinesh for technical help and Drs. Antonio La Cava and Bevra Hahn for intellectual insights.

REFERENCES

1. Dinesh R, Hahn BH, Singh RP. Gender and sex hormones influence CD4+ regulatory T cells and their expression of FoxP3 in healthy people and in SLE. Arthritis Rheum. (2010) 62:1257.
2. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimm Rev. (2010) 9:560–8. doi: 10.1016/j.autrev.2010.03.006
3. Kotzin BL. Systemic lupus erythematosus. Cell. (1996) 85:303–6. doi: 10.1016/S0092-8674(00)81108-3
4. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. (2001) 2:777–80. doi: 10.1038/nii9091-777
5. Ngo ST, Styn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. (2014) 35:347–69. doi: 10.1016/j.y倒塌.2014.04.004
6. Nie J, Li YY, Zhang SG, Tsun A, Li B. FOXP3+CD25+CD4+ regulatory T cells with IL-2 and TGF-beta stimulation in the presence of TGF-[beta]. J Immunol. (2005) 174:1446–55. doi: 10.4049/jimmunol.174.3.1446
7. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for FcepsilonRI in the development and function of human peripheral CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol. (2003) 4:330–6. doi: 10.1038/nri9094
8. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. (2003) 4:337–42. doi: 10.1038/nature02089
9. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. (2003) 198:1875–86. doi: 10.1084/jem.20030152
10. Zheng SG, Wang HJ, Koss MN, Quismino FJ, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol. (2004) 172:1531–9. doi: 10.4049/jimmunol.172.3.1531
11. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Zhang H, et al. TGF-beta induces Foxp3+ T regulatory cells from CD4+CD25- precursors. Am J Transplant. (2004) 4:1614–27. doi: 10.1111/j.1600-6143.2004.00566.x
12. Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by

March 2021 | Volume 12 | Article 619268
Singh and Bischoff

Gender and Regulatory T Cells in SLE

25. Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol. (2005) 175:7728–37. doi: 10.4049/jimmunol.175.11.7728

26. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH. CD8+ T cell-mediated suppression of autokinesis in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol. (2007) 178:7649–57. doi: 10.4049/jimmunol.178.12.7649

27. Singh RP, La Cava A, Hahn BH. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol. (2008) 180:2069–80. doi: 10.4049/jimmunol.180.4.2069

28. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. (2003) 21:273–8. doi: 10.1016/S0892-8648(03)00121-5

29. Liu MF, Wang CR, Fung LL, Wu CR. Deceased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. (2004) 59:198–202. doi: 10.1111/j.0300-9475.2004.01370.x

30. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Role of regulatory T cells in the fatal lymphoproliferative disorder of the scurfy mouse. J Exp Med. (2006) 203:235–44. doi: 10.1084/jem.20061484

31. Ziegler SF. FOXP3: of mice and men. Immunology. (2004) 112:198–206. doi: 10.1111/j.0300-9475.2004.01370.x

32. Bonelli M, Smolen JS, Scheinecker C. Foxp3 regulatory T cells and lupus. Arthritis Res Ther. (2008) 10:227. doi: 10.1186/ar2511

33. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in patients with systemic lupus erythematosus. Adv Med Biol. (2007) 60:113–9. doi: 10.1007/s11517-007-8720-0

34. Arzob NA, Bassouyi IH, Emad Y, Abd El-Wahab GA, Hamdy G, Mashaihi MA. CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol. (2008) 127:151–7. doi: 10.1016/j.clim.2007.12.010

35. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis. (2008) 67:664–71. doi: 10.1136/ard.2007.074690

36. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. (2007) 37:987–96. doi: 10.1111/j.1365-2362.2007.01882.x

37. Yates J, Whittington P, Mitchell P, Lechler RI, Lightstone L, Lombardi G. Natural regulatory T cells: number and function are normal in the aSAH model of active systemic lupus erythematosus. J Autoimmun. (2008) 32:664–7. doi: 10.1016/j.jaut.2008.09.021

38. Ziegler SF, Muenzinger K, Kraybill L, Lanier E, Schirrmann J. Expression of CD25highFoxP3+ regulatory T cells in patients with active systemic lupus erythematosus. J Immunol. (2010) 184:2572–7. doi: 10.4049/jimmunol.184.4.2572

39. Yu M, Wang CR, Fung LL, Wu CR. Deceased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. (2004) 59:198–202. doi: 10.1111/j.0300-9475.2004.01370.x

40. Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine. (1983) 62:327–34. doi: 10.1097/00005924-198309000-00005

41. Lahita RG, Bradlow L, Fishman J, Kunkel HG. Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arthritis Rheum. (1982) 25:843–6. doi: 10.1002/art.1780250726

42. Bonelli N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. (1999) 42:328–37. doi: 10.1002/1529-0131(199902)42:2<328::AID-ANR16>3.0.CO;2-f

43. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol. (1999) 103:282–8. doi: 10.1001/s0091-6749(99)07503-8

44. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. (1987) 30:241–8. doi: 10.1002/art.1780300301

45. Stockand JK, Naka TS, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, et al. Effects of propranolol on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. (2004) 50:2858–68. doi: 10.1002/art.20427

46. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. (1997) 40:1725. doi: 10.1002/art.1780400928

47. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. (1988) 31:312–20. doi: 10.1002/art.1780300301

48. Bomford C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. (1992) 35:630–40. doi: 10.1002/1529-0131(1999)35:6<350::AID-ANR16>3.0.CO;2-f

49. Gorelik L, Flavell RA. Transforming growth factor-beta: the good, the bad, the ugly. Nat Rev Immunol. (2004) 4:198–206. doi: 10.1038/nri1202
82. Geem D, Harusato A, Flannigan K, Denning TL. Harnessing regulatory T cells for the treatment of inflammatory bowel disease.

83. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmune. Semin Immunol. (2011) 23:202–8. doi: 10.1016/j.smim.2011.07.005

84. Pot C, Apetoh L, Awasthi A, Kuchroo VK. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol. (2011) 23:438–45. doi: 10.1016/j.smim.2011.08.003

85. Chen Y, Kuchroo VK, Inobe J, Hafer DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. (1994) 265:1237–40. doi: 10.1126/science.7520605

86. Oda JM, Hirota BK, Guembarovski RL, Watanabe MA. Genetic polymorphism in FOXP3 gene: implication in regulatory T-cell role and development of human diseases. J Genet. (2013) 92:163–71. doi: 10.1007/s12041-013-0213-7

87. Nedoszytko B, Sokołowska-Wojdylo M, Renke J, Lange M, Trzonkowski P, Sobijanek M, et al. The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part III: Polymorphisms of genes involved in Treg's activation and function. Postepy Dermatol Alergor. (2017) 34:517–25. doi: 10.5114/pdia.2017.67053

88. Rider V, Abdou NI, Kimler BF, Lu N, Brown S, Fridley BL. Gender bias in human systemic lupus erythematosus: a problem of steroid receptor action? Front Immunol. (2018) 9:611. doi: 10.3389/fimmu.2018.00611

89. Khan D, Dai R, Ansar Ahmed S. Sex differences and estrogen regulation of miRNAs in lupus, a prototypic autoimmune disease. Cell Immunol. (2015) 294:70–9. doi: 10.1016/j.cellimm.2015.01.004

90. Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. (2018) 9:2279. doi: 10.3389/fimmu.2018.02279

91. Mohammad I, Starskaa I, Nagy T, Guo J, Yatkin E, Vaananen K, et al. Estrogen receptor alpha contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation. Sci Signal. (2018) 11:9415. doi: 10.1126/scisignal.aaw4915

92. Lin YC, Lee JH, Wu AS, Tsai CY, Yu HH, Wang LC, et al. Association of single-nucleotide polymorphisms in FOXP3 gene with systemic lupus erythematosus susceptibility: a case-control study. Lupus. (2011) 20:137–43. doi: 10.1177/0961203310382428

93. Ahmed SA, Hissong BD, Vertelhyi D, Donner K, Becker K, Karpzoglu-Sahin E. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Persp. (1999) 107 Suppl. 5:681–6. doi: 10.1289/ehp.99107s5681

94. Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol. (2006) 176:2703–10. doi: 10.4049/jimmunol.176.5.2703

95. Phiel KL, Henderson RA, Adelman SJ, Eloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. (2005) 97:107–13. doi: 10.1016/j.imlet.2004.10.007

96. Lelu K, Laffont S, Delpy L, Paulet P, Perinat T, Tschanz SA, et al. Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol. (2011) 187:2386–93. doi: 10.4049/jimmunol.1101578

97. Priyanka HP, Krishnan HC, Singh RV, Himla L, Thyagarajan S. Estrogen modulates in vitro T cell responses in a concentration-and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes. Mol Immunol. (2013) 56:328–39. doi: 10.1016/j.molimm.2013.05.226

98. Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein S. 17beta-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs. J Virol. (2014) 88:4711–20. doi: 10.1128/JVI.02081-13

99. Benten WP, Lieberherr M, Giese G, Wunderlich F. Estradiol binding to cell surface raises cytotoxic free calcium in T cells. FEBS Lett. (1998) 422:349–53. doi: 10.1016/S0014-5793(98)00039-8

100. Rider V, Li X, Peterson G, Dawson J, Kimler BF, Abdou NI. Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheum. (2006) 33:1093–101.

101. Tai P, Wang J, Jin H, Song X, Yan J, Kang Y, et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. (2008) 214:5456–64. doi: 10.1002/jcp.21221

102. Polanczyk MJ, Carson BD, Subramanian S, Afentoulis M, Vandenbark AA, Ziegler SE, et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. (2004) 173:2227–30. doi: 10.4049/jimmunol.173.4.2227

103. Shah J, Sakkali A, Kimler BF, Lu N, Brown S, Fridley BL. Estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. (2005) 97:107–13. doi: 10.1016/j.imlet.2004.10.007
103. Morawski PA, Mehra P, Chen C, Bhatti T, Wells AD. Foxp3 protein stability is regulated by cyclin-dependent kinase 2. *J Biol Chem.* (2013) 288:24494–502. doi: 10.1074/jbc.M113.467704

104. Deng G, Nagai Y, Xiao Y, Li Z, Dai S, Ohtani T, et al. Pim-2 kinase influences regulatory T cell function and stability by mediating Foxp3 protein N-terminal phosphorylation. *J Biol Chem.* (2015) 290:20211–20. doi: 10.1074/jbc.M115.638221

105. Yue X, Trifari S, AiJo T, Tsagaratou A, Pastor WA, Zepeda-Martinez JA, et al. Control of Foxp3 stability through modulation of TET activity. *J Exp Med.* (2016) 213:377–97. doi: 10.1084/jem.20151438

106. Someya K, Nakatsukasa H, Ito M, Kondo T, Tateda KI, Akanuma T, et al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. *Int Immunol.* (2017) 29:365–75. doi: 10.1093/intimm/dxx049

107. Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. *Front Immunol.* (2018) 9:794. doi: 10.3389/fimmu.2018.00794

108. Fijak M, Schneider E, Klug J, Bhushan S, Hackstein H, Schuler G, et al. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion. *J Immunol.* (2011) 186:5162–72. doi: 10.4049/jimmunol.1001958

109. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hopes and hopes. *Drugs.* (2014) 74:1195–207. doi: 10.1007/s40265-014-0259-8

110. Lieberman SM, Kreiger PA, Koretzky GA. Reversible lacrimal gland-protective regulatory T-cell dysfunction underlies male-specific autoimmune dacryoadenitis in the non-obese diabetic mouse model of Sjogren syndrome. *Immunology.* (2015) 145:232–41. doi: 10.1111/imm.12439

111. Walecki M, Eisel F, Klug J, Baal N, Paradowska-Dogan A, Wahle E, et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. *Mol Biol Cell.* (2015) 26:2845–57. doi: 10.1091/mbc.E14-08-1323

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Singh and Bischoff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.